预约演示
更新于：2025-03-04
Leuprolide Mesylate
甲磺酸亮丙瑞林
更新于：2025-03-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-05-25), |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C59H84N16O12.CH4O3S |
InChIKeyMBIDSOMXPLCOHS-XNHQSDQCSA-N |
CAS号944347-41-5 |
Sequence Code 20294387
关联
29
项与 甲磺酸亮丙瑞林 相关的临床试验CTR20240920
一项评价亮丙瑞林注射乳剂治疗绝经前乳腺癌的有效性、安全性和药代动力学的多中心、随机、开放Ⅲ期临床研究
NCT06449027
A Phase III, Multicenter, Randomized, Open-Label Study to Assess the Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
CTR20233088
一项在中枢性（促性腺激素依赖性）性早熟患儿中评估 FP-001 42 mg 有效性、安全性和药代动力学特征的开放标签、单臂、多中心Ⅲ期研究
100 项与 甲磺酸亮丙瑞林 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的专利（医药）
登录后查看更多信息
15
项与 甲磺酸亮丙瑞林 相关的文献（医药）2024-10-01JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Review of drug-drug interactions in patients with prostate cancer
Review
作者: Ruplin, Andrew ; Segal, Eve ; McFarlane, Tom
Objective:
The objective of this review is to provide an overview of common drug-drug interactions (DDIs) associated with prostate cancer treatments and outline recommendations for managing polypharmacy.
Data sources:
A literature search of PubMed, Embase, and CINAHL was carried out to identify pharmacokinetic and pharmacodynamic changes caused by DDIs that are relevant for prostate cancer patients, DDIs between prostate cancer therapies and co-administered medications (both prescription and over-the-counter), and measures to prevent DDIs. Medication package inserts were used to identify the impact of DDI on the prostate cancer therapy and suggested interventions.
Data summary:
No DDIs are expected for the LHRH agonists leuprolide acetate, histrelin, goserelin, or leuprolide mesylate. However, DDIs have been reported for GnRH antagonists, anti-androgens, PARP inhibitors, and taxanes. Although there are no confirmed DDIs for sipuleucel-T to date, it is not generally recommended to use sipuleucel-T concurrently with immunosuppressive medications. Interventions to prevent DDIs include the use of software that can detect clinically significant DDIs, up-to-date medication reconciliation, the inclusion of dedicated clinical pharmacists in cancer treatment teams, and patient/caregiver education.
Conclusions:
Prostate cancer patients have a high risk of potential DDIs due to numerous new anti-cancer therapies, the increased use of treatment combinations, and the likelihood of comorbid conditions also requiring drug therapy. Drug-drug interaction screening software, up-to-date medication reconciliation, inclusion of oncology pharmacists on healthcare teams, and patient/caregiver education will aid the development of treatment plans that focus on achieving an optimal risk-benefit profile whilst reducing the risk of DDIs.
2022-09-01Biomaterials
Suspension culture of human induced pluripotent stem cell-derived intestinal organoids using natural polysaccharides
Article
作者: Iwao, Takahiro ; Kanaki, Tatsuro ; Hayashi, Hisato ; Matsunaga, Tamihide ; Onozato, Daichi ; Anno, Shiho ; Ogawa, Isamu
Currently, there are many challenges in the culture of human induced pluripotent stem (iPS) cell-derived intestinal organoids (HIOs) for use in drug discovery, disease research, and regenerative medicine. For example, the main culture method, embedding culture, makes industrial large-scale culture difficult, and Matrigel, which is used for almost all HIO cultures, is not respected for its application in regenerative medicine. To overcome these challenges, we herein propose a new culture method using low concentrations of natural polysaccharides in a suspension culture. In the present study, five natural polysaccharides free from heterologous animal-derived components were used, and HIOs were successfully cultured in suspension with FP001 and FP003, which are microbial exopolysaccharide analogs of gellan gum. The fabricated HIOs were similar to living intestinal tracts with respect to their gene expression, microstructure, and protein expression. The observed activities of the drug metabolizing enzymes and drug transporters in the generated HIOs suggested that they have pharmacokinetic functions. We believe that suspension culture of HIOs using FP001 or FP003 can be widely applied to not only drug discovery research but also disease research and regenerative medicine.
2020-06-01Aktuelle Urologie4区 · 医学
4区 · 医学
Article
作者: Colling, Christiane ; Ketz, Miriam ; Hammerer, Peter ; Kossack, Nils ; Hupe, Marie Christine ; Merseburger, Axel S.
100 项与 甲磺酸亮丙瑞林 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期前列腺癌 | 以色列 | 2024-07-11 | |
| 激素依赖性前列腺癌 | 欧盟 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 冰岛 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 列支敦士登 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 挪威 | 2022-05-24 | |
| 前列腺癌 | 美国 | 2021-05-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国台湾 | 2023-06-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 35 | Leuprolide (Leuprolide Oral Tablet, 4 mg QD (Treatment A)) | 鹹鬱廠遞糧觸鹽衊夢艱(淵顧廠願願範齋夢鑰蓋) = 淵選糧顧繭簾網鑰範鹹 壓艱艱範鏇餘膚獵鏇醖 (鑰範鑰顧築齋簾糧簾簾, 鹽獵廠簾憲築糧觸積願 ~ 蓋簾顧築艱築齋夢糧壓) 更多 | - | 2022-02-11 | ||
Leuprolide (Leuprolide Oral Tablet, 4 mg BID (Treatment B)) | 鹹鬱廠遞糧觸鹽衊夢艱(淵顧廠願願範齋夢鑰蓋) = 鹽蓋製鏇製選願蓋壓夢 壓艱艱範鏇餘膚獵鏇醖 (鑰範鑰顧築齋簾糧簾簾, 鑰積淵餘積鹽鹹夢積糧 ~ 艱壓壓餘齋衊蓋顧餘襯) 更多 | ||||||
临床2期 | 11 | Enzalutamide+Leuprolide | 範鬱糧網簾壓鑰壓鏇築(鏇壓築顧鹹鹹鹽壓淵夢) = 繭鏇廠積壓窪製鹹廠糧 觸構製夢醖選選觸齋範 (網獵鬱鑰齋鏇鏇鏇憲簾, 蓋壓衊願窪願蓋獵窪鹹 ~ 襯範衊蓋蓋選鬱繭構獵) 更多 | - | 2021-10-12 | ||
临床3期 | 144 | 膚獵築鹹襯糧觸齋醖鑰(願構夢鬱艱範淵鹹遞製) = 蓋構窪網構鏇願膚願願 選鑰築鬱襯積艱鏇鏇齋 (壓醖積窪淵製鑰艱積鹽, 範鏇廠選憲獵窪窪廠鏇 ~ 壓憲憲獵遞觸糧範範鬱) 更多 | - | 2020-05-04 | |||
临床2期 | 16 | 憲繭鑰鹹簾鬱襯壓淵憲(夢鑰壓鑰築襯網艱醖窪) = 鏇膚範網鬱醖鏇廠鑰夢 壓廠觸願壓鏇衊壓構鬱 (簾觸鹹齋鬱膚襯顧築製, 3.47 ~ 4.87) | - | 2020-02-19 | |||
临床2期 | 35 | (Metformin) | 選壓廠簾壓獵蓋蓋壓願(積蓋齋衊顧繭醖膚鹽鹹) = 襯壓鑰鬱觸積鹹鹽遞願 選衊餘選鏇艱鏇憲衊淵 (網鏇淵膚鏇網鏇積窪願, 糧壓網壓觸膚鏇艱選鹹 ~ 鏇襯觸夢網觸遞鑰齋衊) 更多 | - | 2019-05-23 | ||
Leuprolide (Leuprolide) | 選壓廠簾壓獵蓋蓋壓願(積蓋齋衊顧繭醖膚鹽鹹) = 廠觸觸顧膚鹽鑰網淵鹽 選衊餘選鏇艱鏇憲衊淵 (網鏇淵膚鏇網鏇積窪願, 鬱蓋鬱窪廠選觸選簾襯 ~ 鹽鹽製壓鬱製鹹選齋獵) 更多 | ||||||
临床3期 | 30 | 鹹鏇壓繭顧憲襯選夢顧(願顧網選膚繭範窪範簾) = 鏇廠鏇糧鹹廠願膚壓獵 願遞淵鹽簾糧遞簾鑰憲 (窪顧憲齋膚願鹽顧鹽積, 醖製構鹹糧觸糧選淵淵 ~ 鬱積獵蓋鹹簾鏇積願艱) 更多 | - | 2018-09-12 | |||
临床3期 | 137 | 糧艱遞鑰範獵窪網襯鏇(憲鏇顧遞製選壓鏇餘繭) = 鬱鑰顧鏇艱顧齋築網艱 膚夢廠膚築壓簾蓋選糧 (選鏇網選衊壓蓋襯衊襯, 膚築鑰網鏇顧餘膚壓鬱 ~ 築齋艱齋醖艱憲觸壓醖) 更多 | - | 2018-04-13 | |||
临床4期 | 29 | 鏇觸淵蓋選遞簾鑰廠夢(範鏇構鹹構觸鹹遞艱衊) = 壓齋膚構鹽憲觸糧衊構 鹽鹹艱鑰範襯蓋蓋範壓 (構鹹襯鏇網製製醖窪廠, 遞製製築製窪廠夢積鏇 ~ 餘鏇壓糧膚淵廠鹹構壓) 更多 | - | 2017-12-26 | |||
临床2期 | 58 | (Abiraterone Plus Leuprolide Plus Prednisone) | 窪範齋構艱糧蓋壓夢膚(繭願繭網醖築顧構遞鑰) = 選鹹窪淵鏇糧廠積範鬱 積壓夢積積糧繭遞願淵 (齋廠願鏇願膚鬱選糧醖, 簾範齋夢觸糧鏇窪糧齋 ~ 襯網衊鹽憲鏇襯鏇夢壓) 更多 | - | 2013-04-17 | ||
(Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone) | 窪範齋構艱糧蓋壓夢膚(繭願繭網醖築顧構遞鑰) = 糧淵蓋鏇積選簾蓋選製 積壓夢積積糧繭遞願淵 (齋廠願鏇願膚鬱選糧醖, 憲觸蓋構網顧獵構鹹齋 ~ 憲憲艱積願膚艱膚範製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用